Marinomed Biotech has announced a new agreement with VitaPlus for distribution of one of Marionomed’s Carragelose nasal sprays in Hungary and another agreement with GAIA Healthcare for marketing of two Carragelose nasal sprays in the Gulf region. According to the announcement, VitaPlus could launch the nasal spray by the end of this year, and GAIA will be submitting marketing applications for the nasal sprays in Gulf countries, with the hopes of launching a product as early as 2025.
The iota-carrageenan nasal sprays are marketed over the counter for the prevention and treatment of respiratory viruses, with partnerships in more than 40 countries, the company says. In December 2023, Marinomed announced that Favorex had acquired rights to Carragelose nasal sprays in Thailand, Malaysia, Myanmar, and the Philippines. M8 has the Brazilian and Mexican rights, and Perrigo markets Carragelose nasal spray in European countries as “Physiomer Virus Defense.”
Marinomed CEO Andreas Grassauer commented, “By adding renowned and reliable partners such as GAIA and VitaPlus to our Carragelose distribution network, we are following our strategy of further expanding our market reach and introducing additional products in existing markets. We will probably see first revenues from our partnership with VitaPlus as early as this year, due to existing regulatory approvals in the EU. Overall, we are pleased with the development of our Carragelose business by expanding our geographical reach to interesting pharmaceuticals markets like the Gulf Region and Eastern Europe. At the same time, we are also making steady progress with our new allergy and eye care products as well as with our partner Procter & Gamble for the US.”
Read the Marinomed press release.
